|  | 
|  | 
|  | 
| Originator Org.- | 
|  | 
| Inactive Indication- | 
| Drug Highest PhaseApproved | 
| First Approval Ctry. / Loc.Japan | 
| First Approval Date27 Aug 1965 | 
以复方氨基酸注射液(9AA)为对照评价肾病用氨基酸注射液(17AA-II)治疗肾功能不全的有效性和安全性临床试验
 [Translation] Clinical trial to evaluate the efficacy and safety of amino acid injection (17AA-II) for kidney disease in the treatment of renal insufficiency using compound amino acid injection (9AA) as a control 
评价天津药业研究院有限公司研制的肾病用氨基酸注射液(17AA-II)配合低蛋白饮食治疗肾功能不全的有效性和安全性。
 [Translation] To evaluate the efficacy and safety of amino acid injection for renal disease (17AA-II) developed by Tianjin Pharmaceutical Research Institute Co., Ltd. combined with a low-protein diet in the treatment of renal insufficiency. 
 100 Clinical Results associated with Tianjin Tianan Pharmaceutical Co. Ltd.
0  Patents (Medical) associated with Tianjin Tianan Pharmaceutical Co. Ltd.
100 Deals associated with Tianjin Tianan Pharmaceutical Co. Ltd.
100 Translational Medicine associated with Tianjin Tianan Pharmaceutical Co. Ltd.